Overview

Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

Status:
Recruiting

Trial end date:
2024-01-31

Target enrollment:

Participant gender:

Summary

The primary hypothesis is that the objective response rate (ORR) with nab-paclitaxel and nivolumab will be significantly higher than the historical control (ORR 30%). The KEY secondary hypothesis is that the median PFS with nab-paclitaxel and nivolumab will be significantly longer than the historical control (median PFS 3.6 months).

Phase:

Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Collaborator:

Bristol-Myers Squibb

Treatments:

Nivolumab
Paclitaxel